Symphogen
Christine Enoch Nielsen has extensive experience as a Laboratory Technician. Christine began their career in 1996 at Novozymes/Novo Nordisk and worked there until 2005. Christine then joined Novozymes and worked as a Laboratory Technician until 2012. During their time at Novozymes, they were involved in various projects, including developing in vitro assays for testing peptides related to inflammation and implementing tissue-based assays for testing enzyme allergenicity.
In 2012, Christine joined Novo Nordisk as a Laboratory Technician. Here, they focused on diabetes complications biology, specifically related to diabetic kidney disease. Christine'sresponsibilities included cell culture and in vitro assays to test the effects of various stimuli on cellular targets, as well as RNA purification from mouse organs to study changes in gene expression. Christine also worked with migration assays, adhesion assays, flow cytometry, and various other techniques.
In 2017, Christine moved to CytoVac, where they worked as a Laborant. Christine stayed with the company until 2018 before joining Symphogen as a Laboratory Technician. The details of their roles at these companies are not provided.
From 1993 to 1996, Christine Enoch Nielsen attended Rigshospitalet i Glostrup, where they pursued a degree in Hospitalslaborant with a focus on Klinisk Kemisk Afdeling.
This person is not in the org chart
This person is not in any offices
Symphogen
3 followers
Symphogen is a clinical-stage antibody oncology focused company with a differentiated product pipeline and significant commercial opportunities. Inspired by nature, led by science and driven by people, we passionately strive to make that discovery that may have great effect on the lives of patients, their families, and their caregivers. Based on our monoclonal antibody (mAb) research platform, we create differentiated mAb and mAb mixture products candidates. Our pre-clinical and clinical pipeline is well suited for a precision-medicine approach by addressing well-defined, biomarker-selected patient populations. We are headquartered in Denmark with operations in the US.